Comparison of 68Ga-DOTA-JR11 PET/CT with dosimetric 177Lu-satoreotide tetraxetan (177Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.
Simone KrebsJoseph A O'DonoghueEvan BiegelBradley J BeattieDiane ReidySerge K LyashchenkoJason S LewisLisa BodeiWolfgang A WeberNeeta Pandit-TaskarPublished in: European journal of nuclear medicine and molecular imaging (2020)
Our study shows that 68Ga-DOTA-JR11 PET can be used for patient selection and PRRT and that low tumor uptake on PET should not preclude patients from treatment with 177Lu-satoreotide tetraxetan. The ability to use single time-point SPECT/CT for absorbed dose calculations could facilitate dosimetry regimens, save costs, and improve patient convenience.
Keyphrases
- pet ct
- positron emission tomography
- neuroendocrine tumors
- end stage renal disease
- computed tomography
- case report
- image quality
- ejection fraction
- newly diagnosed
- dual energy
- chronic kidney disease
- radiation therapy
- contrast enhanced
- peritoneal dialysis
- monte carlo
- magnetic resonance imaging
- molecular dynamics
- molecular dynamics simulations
- combination therapy
- binding protein